Samyang Biopharm Corporation
Financials
Valuation Metrics
Samyang Biopharm Corporation's Market Cap is ₩2926B. Ranked #619 of 2,410 in KR market (top 26%), #366 of 779 on KOSPI (top 47%), #66 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 29%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 292.60B KRW | KR#619/2,410 Sec#66/231 |
| Revenue | 28.59B KRW | KR#2,038/2,410 Sec#141/231 |
| Net Income | 2.24B KRW | KR#1,392/2,410 Sec#97/231 |
| Total Assets | 339.28B KRW | KR#969/2,410 Sec#60/231 |
| Net Assets | 234.73B KRW | KR#859/2,410 Sec#57/231 |
| Value | ||
| P/E | 130.83x | KR#1,508/2,410 Sec#100/231 |
| P/B | 1.25x | KR#1,712/2,410 Sec#114/231 |
| P/S | 10.23x | KR#2,281/2,410 Sec#167/231 |
| EV/EBITDA | 126.61x | KR#1,511/2,410 Sec#102/231 |
| FCF Yield | 1.04% | KR#1,137/2,410 Sec#83/231 |
| Profitability | ||
| ROE | 0.95% | KR#1,486/2,410 Sec#103/231 |
| ROA | 0.66% | KR#1,450/2,410 Sec#102/231 |
| Op. Margin | 9.41% | KR#562/2,410 Sec#47/231 |
| Financial Health | ||
| Debt Ratio | 44.54% | KR#875/2,410 Sec#101/231 |
| Total Debt | 77.82B KRW | KR#819/2,410 Sec#51/231 |
| FCF | 3.05B KRW | KR#1,016/2,410 Sec#72/231 |
| Cash | 29.68B KRW | KR#1,018/2,410 Sec#70/231 |
| Current Ratio | 1.68x | KR#1,046/2,410 Sec#119/231 |
| Net Debt/EBITDA | 17.89x | KR#1,351/2,410 Sec#96/231 |
| Performance | ||
| 1M Return | -18.70% | KR#1,773/2,410 Sec#173/231 |
| From 52W High | -73.92% | KR#2,166/2,410 Sec#194/231 |
| 1Y MDD | -76.24% | KR#2,185/2,410 Sec#191/231 |
| Trading | ||
| Volume | 21,167 shares | KR#1,342/2,410 Sec#135/231 |
| Trading Value | 827.6M KRW | KR#567/2,410 Sec#59/231 |
| Foreign Own. | 2.84% | KR#1,336/2,410 Sec#121/231 |
| Per Share | ||
| EPS | 301 KRW | KR#1,175/2,410 Sec#81/231 |
| BPS | 31,568 KRW | KR#356/2,410 Sec#25/231 |
Company Info
Samyang Biopharm is a company operating in the pharmaceutical bio business, newly established through a spin-off from Samyang Holdings. It develops new drugs and improved new drugs based on innovative technologies, including drug delivery platforms (DDS), polymer nanoparticle technology, and siRNA/mRNA-based delivery technology. The company holds the top position in the domestic cytotoxic anticancer drug market (with Genexol, Pemed) and the global biodegradable suture thread market, demonstrating high technological capabilities and market share. Samyang Biopharm was established in 2025 and is headquartered in Seongnam-si, Gyeonggi-do.